BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35584337)

  • 1. Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data.
    Waheed A; Rodday AM; Kumar AJ; Miller KB; Parsons SK
    JCO Clin Cancer Inform; 2022 May; 6():e2100135. PubMed ID: 35584337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
    Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States.
    Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    Clin Ther; 2017 Feb; 39(2):303-310. PubMed ID: 28065438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
    Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
    Kumar AJ; Chao CR; Rodday AM; Chang H; Xu L; Evens AM; Parsons SK
    Leuk Lymphoma; 2022 May; 63(5):1119-1126. PubMed ID: 34886751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine.
    Amer R; Salameh H; Mosleh S; Abu-Taha A; Hamayel H; Enaya A; Adas A; Khursani A; Wild-Ali M; Mousa T; Battat M; Daifallah A; Koni A; Shawahna R
    BMC Infect Dis; 2022 Sep; 22(1):725. PubMed ID: 36071381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
    Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
    Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
    Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Dec; 38(5):737-741. PubMed ID: 32905626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.